Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Protein unc-13 homolog C (UNC13C)
- Target
- UNC13C
- Molecular classification
- Other (specifically, Presynaptic active zone protein within the synaptic vesicle exocytosis machinery; not classified under receptor, enzyme, GPCR, transporter, ion channel, or transcription factor[3][4].)
01
Overview
Protein unc-13 homolog C (UNC13C), also known as Munc13-3, is a member of the Munc13 protein family that plays a critical role in the priming and regulation of synaptic vesicle exocytosis at presynaptic active zones in neurons[3][4][6]. UNC13C is essential for proper neurotransmitter release, particularly glutamate, and is highly expressed in the cerebellum where it is localized to the synaptic terminals of granule and Purkinje cells[3][4][6]. Its action is mediated through vesicle priming, facilitating SNARE complex assembly, and interacting with the diacylglycerol (DAG) pathway via its C1 and C2 domains, which are capable of calcium binding[3][5]. Loss of function in animal models results in reduced neurotransmitter release probability and impaired motor learning, but does not cause overt neurodevelopmental defects, likely due to redundancy among the Munc13 protein family members[4][6]. At present, UNC13C is not an established drug target or biomarker and has no known interacting therapeutics[3][4][6].
- Other names
- Munc13-3unc-13 homolog CDKFZp547H074protein unc-13 homolog Cunc-13-like 3
02
Mechanism of action
Not applicable. (No drugs reported to act on this protein.)
03
Biological functions
Synaptic vesicle primingRegulation of neurotransmitter releaseVesicle maturation during exocytosis[3][4][6]Calcium ion binding (through C2 domains)[3][5]Putative regulation of cerebellar motor learning[4][6]
04
Disease associations
Neurodegenerative disease (impaired synaptic transmission is linked to neurological dysfunction, especially in the cerebellum with impaired motor learning in knockout mice[4][6])Other (possible implication in neurological or psychiatric disease, but not directly causal nor established as a disease gene in common conditions[4].)
05
Safety considerations
No specific safety concerns related to UNC13C as a drug target have been described, as it is not a target for therapeutic intervention[4][6].
Beyond the preview
Go deeper on Protein unc-13 homolog C (UNC13C).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Protein unc-13 homolog C (UNC13C).